Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOMeLSD, Psilocin, 25I-NBOMe +4 moreLSD, Psilocin, 25I-NBOMe, 25B-NBOMe, 25C-NBOMe, DOI, Mescaline show less
25E-NBOMe
4-ethyl-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
25E-NBOMe is a synthetic psychedelic of the phenethylamine class. It is the N-(2-methoxybenzyl) derivative of 2C-E, a member of the NBOMe series known for microgram-range potency. It activates serotonin receptors in the brain, producing the visual distortions and altered cognition characteristic of psychedelics.[1]
25E-NBOMe is a synthetic psychedelic of the phenethylamine class. It is the N-(2-methoxybenzyl) derivative of 2C-E, a member of the NBOMe series distinguished by microgram-range potency. 25E-NBOMe is a full agonist at 5-HT₂A receptors, producing its effects by amplifying serotonergic signaling in cortical neural circuits.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOMeLSD, Psilocin, 25I-NBOMe +4 moreLSD, Psilocin, 25I-NBOMe, 25B-NBOMe, 25C-NBOMe, DOI, Mescaline show less
The NBOMe scaffold was created by Ralf Heim in 2003 as a research tool for brain imaging, not as a recreational drug.[2] In the early 2010s, 25E-NBOMe began appearing on illicit markets, typically sold as LSD on blotter paper.[3] It remains unscheduled by name in most countries but is controlled under structural analog provisions in the United States, United Kingdom, and Canada.
Subjective effects include geometric visual patterns, brightened colors, euphoria, and a buzzing physical energy. The experience is physically pronounced and stimulating — shorter and more body-heavy than LSD, with an intensity that rises steeply with dose. Vasoconstriction, anxiety, confusion, and a bitter numbing taste on contact are characteristic unsought effects.
No physical dependence develops; tolerance builds quickly after use,[4] but the NBOMe class has caused confirmed fatalities via closely related compounds.[5][6] The core danger is dosing unpredictability — microgram potency and uneven blotter distribution can deliver far more than intended in a single tab.[7] Almost nothing has been measured directly in humans; all risk estimates come from analogy to related compounds.
History[edit]
Discovery
Alexander Shulgin first synthesized the parent compound 2C-E and documented it in PiHKAL.[8] In 2003, Ralf Heim attached a 2-methoxybenzyl group to compounds like 2C-E, dramatically increasing their affinity for serotonin receptors.[2] Heim's goal was brain imaging research — he did not investigate or anticipate recreational use.
Market emergence
NBOMe compounds appeared on illicit markets in the early 2010s, sold through online research chemical vendors.[5][9] 25E-NBOMe was first analytically confirmed in seized blotter papers in Poland in 2013.[3] These compounds were routinely sold as LSD — a misrepresentation that contributed to hospitalizations and deaths involving 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe, though no deaths have been attributed to 25E-NBOMe specifically.[6][9]
Prohibition
The United States permanently placed 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe in Schedule I in September 2016.[10] 25E-NBOMe was not named but remains prosecutable as an structural analog. The United Kingdom classified all N-benzylphenethylamine derivatives as Class A in June 2014, and Brazil explicitly scheduled 25E-NBOMe by name in February 2014.[11]
Chemistry[edit]
Structural class
25E-NBOMe belongs to the 25x-NBOMe series — synthetic phenethylamines derived from the 2C family of compounds. It is produced by attaching a 2-methoxybenzyl group to 2C-E, a modification that dramatically increases its affinity for serotonin receptors.[12] Its molecular formula is C₂₀H₂₇NO₃ (molecular weight 329.4 g/mol).
Molecular properties
25E-NBOMe has no chirality centers — it exists as a single species without mirror-image variants. The compound has only been encountered as blotter paper preparations in forensic seizures.[3] Definitive identification requires specialized laboratory methods; the compound's mass spectral fragments overlap with related NBOMe compounds, making field tests insufficient for specific identification.[3]
Pharmacology[edit]
Mechanism of action
25E-NBOMe is a full agonist at serotonin receptors.[1] It activates these receptors on neurons in the prefrontal cortex, increasing glutamate release and disrupting the brain's normal filtering of sensory information.[13] Rodent studies confirmed that blocking serotonin receptors eliminates its hallucinogenic behavioral signature.[14]
Beyond serotonin, the compound also modulates dopamine. Rodent research found it reduced dopamine in the brain's reward center while increasing dopamine receptor sensitivity.[14] These findings are from animal studies only; their relevance to human pharmacology is unknown.
Pharmacokinetics
NBOMe compounds are inactive when swallowed;[5] active routes include sublingual absorption, nasal insufflation, smoking, and injection. Sublingual onset begins around 15 minutes, with effects lasting 4–10 hours.[15] No human pharmacokinetic data exist — liver metabolism studies identified at least 26 breakdown products including 2C-E itself,[16] but timing and clearance remain unmeasured in any species.
Neuroscience[edit]
Where it acts
No neuroimaging studies have been done with 25E-NBOMe. In closely related 25I-NBOMe, the compound increased dopamine, serotonin, and glutamate in the prefrontal cortex, with hallucinogenic effects tied specifically to the glutamate increase.[13] The result is a disruption of the brain's normal sensory filtering — more information comes through than the brain can organize.
Why it matters
25E-NBOMe also reduces dopamine in the brain's reward center while increasing the sensitivity of dopamine receptors.[14][17] This pattern is unusual for classical psychedelics and may mean the compound engages reward circuitry differently — though its significance for human use is unknown.
- Does 25E-NBOMe produce the cortical entropy increase and default mode network changes seen with other psychedelics?
- Is the dopamine-dependent mesolimbic pathway found in rodents[14] relevant to human abuse potential, or an artifact of the animal model?
- Does the unique metabolic pathway identified for 25E-NBOMe[16] produce active or toxic metabolites?
Subjective Effects[edit]
25E-NBOMe produces a physically heavy, energized psychedelic state. A buzzing body energy and noticeable cardiovascular drive underlie the visual and cognitive alterations. The dose-response curve is steep — manageable color enhancement at low doses can shift quickly into overwhelming sensory distortion at higher amounts.
Within the NBOMe series, 25E-NBOMe reportedly sits between 25I-NBOMe (more visually intense) and 25B-NBOMe (more body-dominant), though this positioning rests on user reports. Compared to LSD, the experience is shorter, more physically pronounced, and less cognitively layered.
The NBOMe scaffold was first synthesized by Ralf Heim in 2003 as a candidate radioligand for brain imaging.[2] 25E-NBOMe appeared on illicit markets in the early 2010s, commonly sold as LSD on blotter paper.[3] It remains unscheduled by name in most jurisdictions but is controlled under structural analog provisions or structural catch-all clauses in the United States, United Kingdom, and Canada.
Subjective effects include geometric visual patterns, color enhancement, euphoria, and body load. The experience carries a distinctly stimulating, body-heavy character relative to classical tryptamine psychedelics, with a bitter numbing taste on sublingual contact that marks the NBOMe class. Vasoconstriction, cardiovascular stimulation, anxiety, and confusion at higher doses are characteristic unsought effects.
No physical dependence is expected — rapid tolerance develops after a single dose[4] — but the NBOMe class carries a dangerous acute toxicity profile, with confirmed fatalities involving closely related congeners.[5][6] Microgram-range active doses combined with uneven distribution on blotter paper create a narrow margin of safety where a single tab may deliver far more than intended.[7] Nearly every pharmacological and toxicological parameter for 25E-NBOMe remains uncharacterized in humans — all safety estimates rest on class-level extrapolation.
History[edit]
Discovery
The parent compound 2C-E was first synthesized and self-assayed by Alexander Shulgin, documented in PiHKAL.[8] The N-(2-methoxybenzyl) modification defining the NBOMe class was introduced by Ralf Heim at the Free University of Berlin in 2003, as part of doctoral research on radioligands for 5-HT₂A receptor imaging.[2] Heim's work was pharmacological tool development — the N-benzylation dramatically increased receptor affinity, producing candidates for positron emission tomography. He did not investigate or anticipate recreational use.
Market emergence
NBOMe compounds appeared on illicit drug markets in the early 2010s,[5] distributed by online research chemical vendors.[9] 25E-NBOMe was first analytically confirmed from seized blotter papers in Poland in 2013.[3] Throughout this period, NBOMe compounds were commonly sold as LSD, exploiting their microgram-range potency and blotter-compatible form[6][9] — a misrepresentation that contributed to hospitalizations and fatalities involving 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe, though no deaths have been attributed specifically to 25E-NBOMe.
Prohibition
Regulatory action targeted the more prevalent congeners first. The United States permanently placed 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe in Schedule I in September 2016.[10] 25E-NBOMe was not explicitly named but remains prosecutable under the Federal Analogue Act. The United Kingdom classified all N-benzylphenethylamine derivatives as Class A in June 2014, and Brazil explicitly scheduled 25E-NBOMe by name in February 2014 — among the first jurisdictions to do so.[11]
Chemistry[edit]
Structural class
25E-NBOMe is a substituted phenethylamine and member of the 25x-NBOMe series — N-(2-methoxybenzyl) derivatives of the 2C compounds. It is derived from 2C-E by attaching a 2-methoxybenzyl group to the amine nitrogen, a modification that dramatically increases 5-HT₂A receptor affinity compared to the parent compound.[12]
Molecular properties
| Molecular formula | C₂₀H₂₇NO₃ |
| Molecular weight | 329.4 g/mol |
The molecule consists of a 2,5-dimethoxyphenethylamine core with a 4-ethyl substituent on the aromatic ring and an N-(2-methoxybenzyl) group on the nitrogen. Three methoxy groups and the ethyl chain define the compound's lipophilicity and receptor binding characteristics. Definitive identification requires LC-MS/MS or NMR, as dominant mass spectral fragments overlap with related NBOMe compounds.[3]
Stereochemistry
25E-NBOMe contains no chirality centers. The compound exists as a single achiral species; enantiomeric considerations do not apply.
Physical properties
No published characterization of physical properties (melting point, solubility, stability) exists for 25E-NBOMe in free base or salt form. The compound has been encountered exclusively as blotter paper preparations in forensic seizures.[3]
Pharmacology[edit]
Mechanism of action
25E-NBOMe acts as a full agonist at serotonin 5-HT₂A receptors — the primary molecular target responsible for hallucinogenic effects.[1] It binds with very high potency at both 5-HT₂A and 5-HT₂C receptors, with negligible activity at monoamine transporters — a profile consistent with hallucinogenic activity without significant stimulant properties.[1]
Activation of 5-HT₂A receptors on neurons in the prefrontal cortex increases glutamate release, proposed as the proximal mechanism underlying hallucinogenic perception.[13] In rodent studies, the hallucinogenic-proxy behavior produced by 25E-NBOMe was blocked by a selective 5-HT₂A antagonist, confirming the receptor dependence of its effects.[14]
Beyond serotonin activity, 25E-NBOMe modulates the dopamine system. Rodent research found it reduced dopamine levels in the nucleus accumbens while increasing D1 receptor expression and activating downstream signaling.[14] Reward-seeking behavior in these animals was blocked by D1 receptor antagonism, suggesting a dopamine-dependent reinforcement pathway atypical for classical psychedelics.[14] These findings are from male rodents only; relevance to human pharmacology is unestablished.
Pharmacokinetics
No human pharmacokinetic data exist for 25E-NBOMe. Bioavailability, peak concentration, half-life, and clearance have not been measured in any species.
NBOMe compounds as a class are inactive when swallowed — the specific mechanism remains unelucidated.[5] Active routes include sublingual/buccal absorption, nasal insufflation, intravenous injection, and smoking.[5] Sublingual onset is approximately 15 minutes, with total duration of 4–10 hours.[15]
Liver metabolism studies identified 26 Phase I metabolites, with principal pathways including O-demethylation, N-dealkylation, and hydroxylation.[16] The parent compound 2C-E was detected among these metabolites, confirming N-dealkylation as a major route.[16] The specific liver enzymes responsible have not been identified, though O-demethylation in related compounds is generally attributed to CYP2D6 and CYP3A4.inferred
Neuroscience[edit]
Where it acts
No neuroimaging studies have been conducted with 25E-NBOMe. In closely related 25I-NBOMe, administration increased extracellular dopamine, serotonin, and glutamate in the prefrontal cortex, with the hallucinogenic-proxy behavior selectively tied to increased glutamate release.[13] This supports a model in which 5-HT₂A activation on cortical neurons disinhibits glutamate transmission, disrupting the brain's normal filtering of sensory information and increasing neural entropy.
25E-NBOMe also modulates the mesolimbic dopamine system, reducing dopamine levels in the nucleus accumbens while upregulating D1 receptors — a compensatory plasticity pattern that may engage reward circuitry atypical for classical psychedelics.[14][17]
Why it matters
The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A agonists reduce the brain's confidence in its existing predictions, loosening top-down constraints on perception and thought. As a potent full 5-HT₂A agonist, 25E-NBOMe would be expected to engage this mechanism, though no brain imaging data confirm it.citation needed
Separately, 5-HT₂A agonists in the psychedelic class promote rapid neural rewiring — new dendritic connections and synapse formation — via growth-factor signaling cascades. Whether 25E-NBOMe drives this neuroplasticity has not been tested directly, though its full agonist profile suggests comparable potential.citation needed
- Does 25E-NBOMe produce the cortical entropy increase and default mode network changes seen with other psychedelics?
- Is the D1-dependent mesolimbic pathway found in rodents[14] relevant to human abuse potential, or an artifact of the animal model?
- Does the unique metabolic pathway identified for 25E-NBOMe[16] produce active or toxic metabolites?
Subjective Effects[edit]
The 25E-NBOMe experience is defined by stimulation and somatic weight. Where classical tryptamine psychedelics tend toward introspection and sedation, this compound pushes outward — a buzzing physical energy underlies the visual and cognitive alterations, accompanied by noticeable cardiovascular drive and vasoconstriction. The dose-response curve is steep: low doses produce manageable color enhancement and mood lift, while moderate-to-high doses can shift rapidly into overwhelming sensory distortion and physical discomfort. Set and setting exert strong influence, and the compound's narrow safety margin amplifies the stakes of uncontrolled environments.
Within the NBOMe series, 25E-NBOMe occupies a middle ground — reportedly less visually intense than 25I-NBOMe and less body-dominant than 25B-NBOMe, though this positioning rests entirely on user reports. Compared to LSD, the experience is shorter, more physically pronounced, and less cognitively layered.
Effect Grid
Clear visual effects emerge: visual drifting, breathing surfaces, geometric overlays, color enhancement, and environmental patterning are prominent. Internal hallucinations become accessible with closed eyes. Auditory enhancement and mild auditory distortion may occur. Cognitive shifts include thought acceleration, enhanced pattern recognition, creativity enhancement, and emotional amplification. Time alteration is noticeable.
Physical effects are pronounced — significant body high with stimulation, vasoconstriction producing noticeably cold extremities, muscle tension, pupil dilation, and increased heart rate. Appetite suppression and wakefulness are reliable. Nausea is possible, particularly during the come-up phase.
The experience demands a full day's commitment. Functional impairment is significant and sleep is unlikely for 6–10 hours. The narrow margin of safety means precise dosing is critical at this range.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Environmental patterning · Symmetrical texture repetition · Brightness alteration · Tracers · Visual breathing · Visual morphing · Music enhancement · After-images · Auditory enhancement · Depth perception distortion · Light sensitivity · Visual diffraction · Perspective distortion · Sound sensitivity · Spatial disorientation · Visual melting · Auditory distortion · Auditory misinterpretation · Peripheral vision distortion · Visual haze / noise · Touch enhancement · Vestibular distortion · Proprioceptive distortion · Visual processing acceleration · Synesthesia · Flashbacks · Object transformations · Visual recursion · Internal hallucinations · External hallucinations · Object activation · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Visual breathing · Visual morphing · Music enhancement · After-images · Auditory enhancement · Depth perception distortion · Light sensitivity · Visual diffraction · Perspective distortion · Sound sensitivity · Spatial disorientation · Visual melting · Auditory distortion · Auditory misinterpretation · Peripheral vision distortion · Visual haze / noise · Touch enhancement · Vestibular distortion · Proprioceptive distortion · Visual processing acceleration · Synesthesia · Flashbacks · Object transformations · Visual recursion · Internal hallucinations · External hallucinations · Object activation · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Heart rate perception changes · Appetite suppression · Body high · Restlessness · Dry mouth · Excessive sweating · Spontaneous body sensations · Physical fatigue · Nausea · Tingling / electric sensations · Vibrations / buzzing · Insomnia · Tactile euphoria · Dizziness · Nystagmus (eye wobbles) · Bruxism · Laughter fits · Body schema distortion · Headache · Involuntary body movements · Bodily pressures · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Dry mouth · Excessive sweating · Spontaneous body sensations · Physical fatigue · Nausea · Tingling / electric sensations · Vibrations / buzzing · Insomnia · Tactile euphoria · Dizziness · Nystagmus (eye wobbles) · Bruxism · Laughter fits · Body schema distortion · Headache · Involuntary body movements · Bodily pressures · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Cognitive impairment · Confusion · Immersion enhancement · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Thought acceleration · Thought connectivity · Cognitive fatigue · Openness enhancement · Thought disorganization · Thought loops · Conceptual thinking · Introspection enhancement · Increased nature relatedness · Information processing suppression · Focus suppression · Memory fragmentation · Creativity enhancement · Humor enhancement · Memory suppression · Analysis suppression · Language suppression · Synchronicity · Motivation suppression · Cognitive dysphoria · Delusions · Delirium
Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Thought acceleration · Thought connectivity · Cognitive fatigue · Openness enhancement · Thought disorganization · Thought loops · Conceptual thinking · Introspection enhancement · Increased nature relatedness · Information processing suppression · Focus suppression · Memory fragmentation · Creativity enhancement · Humor enhancement · Memory suppression · Analysis suppression · Language suppression · Synchronicity · Motivation suppression · Cognitive dysphoria · Delirium
Emotional lability · Empathy enhancement · Simultaneous emotions · Dysphoria · Irritability
Irritability
Communication suppression · Sociability suppression · Social disconnection · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration
Cognitive disconnection · Ego dissolution · Identity alteration
Timeline
Rapid nasal burning and irritation. Immediate alertness and quick body load onset. Effects begin noticeably faster than sublingual route.
Fast visual and somatic escalation. Intense vasoconstriction and cardiovascular stimulation build rapidly. The compressed come-up increases overwhelm risk.
Compressed, intense peak comparable to sublingual but reached faster. Full visual effects, maximum body load, and strongest cognitive/emotional shifts. Higher overwhelm risk due to rapid onset.
Gradual decline of visual and cognitive effects. Persistent physical stimulation and vasoconstriction. Emotional sensitivity wanes.
Residual stimulation and physical fatigue similar to sublingual afterglow. Mild visual enhancement may persist.
⚠ Do not drive or operate machinery for at least 10 hours after administration.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- LSD · Psilocin · 25I-NBOMe
Toxicity
No controlled toxicity data exist for 25E-NBOMe specifically, and no deaths have been attributed to it alone.safety citation needed The NBOMe class produces a consistent toxic pattern: rapid heart rate, high blood pressure, dangerously elevated body temperature, sweating, dilated pupils, agitation, and seizures.[5][17][15]
Severe complications
Severe outcomes documented for other NBOMe compounds include muscle breakdown (from seizures, overheating, and vasoconstriction),[9] blood clotting dysfunction, dangerously low blood sugar, and organ failure.[5] Fatalities have been confirmed for 25B-NBOMe and 25I-NBOMe.[6] Animal data show the broader NBOMe class causes developmental harm and cardiovascular toxicity.[17]
Dosing unpredictability
Uneven distribution of compound on blotter paper creates inherent overdose risk — individual tabs from the same sheet may contain far more than intended.[7] At microgram-range active doses, this variability narrows the safety margin substantially.
Detection
25E-NBOMe does not appear on standard drug screens.[18] Confirmation requires specialized laboratory analysis with appropriate reference standards.[19][3]
Psychological Risks
Acute psychological adverse effects include severe anxiety, panic attacks, hallucinations, paranoid thinking, and violent agitation.[5][17] Agitation and uncontrollable behavior are more prominent with NBOMe compounds than with classical psychedelics like LSD or psilocybin, likely reflecting the broader receptor profile.[17]
Persistent visual disturbances and lasting psychosis have been reported for the NBOMe class. No published case reports of these lasting effects specific to 25E-NBOMe were identified.safety citation needed
Tolerance & Dependence
Tolerance builds rapidly after a single dose via serotonin downregulation.[4] Cross-tolerance exists with other serotonergic psychedelics — recent use of LSD, psilocin, or 25I-NBOMe will blunt effects and vice versa.[4]inferred
Physical dependence is not expected based on psychedelic class pharmacology. Rodent studies found reward-seeking behavior driven by a dopamine signaling pathway,[14] but no human dependence or withdrawal cases have been reported for 25E-NBOMe or the broader NBOMe class.
Drug Interactions
No human drug interaction studies exist for 25E-NBOMe. The following are inferred from its mechanism.inferred
Serotonergic drugs: Combining with any drug that raises serotonin — including MAOIs, SSRIs, SNRIs, tricyclic antidepressants, lithium, tramadol, triptans, and MDMA — risks dangerous serotonin overload that can cause overheating, seizures, and death.[17][5]safety citation needed
Lithium: Anecdotally linked to increased seizure risk with serotonergic psychedelics. NBOMe compounds independently lower the seizure threshold, making this combination particularly dangerous.safety citation needed
CYP2D6 and CYP3A4 inhibitors: Drugs that slow these liver enzymes — including fluoxetine, paroxetine, bupropion, and ketoconazole — could increase the compound's concentration in the body and raise toxicity risk.inferred
Stimulants: Combining with cocaine or amphetamines compounds cardiovascular toxicity through additive stimulation — dangerously high blood pressure, elevated body temperature, and rapid heart rate.inferred
Cannabis: May unpredictably intensify or alter the psychedelic experience.citation needed
Contraindications
10 knownNo substance-specific contraindication data exist. The following are inferred from NBOMe class pharmacology.inferred
Heart conditions: High blood pressure, rapid heart rate, and blood vessel constriction make 25E-NBOMe contraindicated for those with pre-existing cardiovascular disease.[5]
Seizure disorders: NBOMe compounds lower the seizure threshold — epilepsy or any seizure predisposition is a contraindication.[5][17]
Psychotic disorders: Personal or family history of schizophrenia or schizoaffective disorder is a contraindication given the psychosis potential of potent serotonin agonists.[17]
Concurrent serotonergic medications: MAOIs, SSRIs, SNRIs, or lithium are contraindicated due to the risk of dangerous serotonin overload.safety citation needed
Liver impairment: 25E-NBOMe is extensively processed by the liver.[16] Impaired liver function could reduce clearance and increase toxicity.
Pregnancy: Animal data show developmental harm from NBOMe exposure.[17]
Harm Reduction[edit]
Forms & Identification
25E-NBOMe appears on blotter paper indistinguishable from LSD. A pronounced bitter, numbing taste on sublingual contact is the most immediate sign that a blotter contains an NBOMe compound rather than LSD, which is tasteless. Reagent testing can distinguish NBOMe compounds from LSD but cannot identify which specific NBOMe series member is present.
Guidelines
- Test every blotter with a reagent kit before use — a bitter, numbing taste on contact indicates an NBOMe compound, not LSD
- Start with the lowest available dose; do not redose during the experience
- Choose a calm, temperature-controlled indoor environment
- Ensure a sober, trusted sitter is present who knows what was taken and when
- Stay hydrated with moderate, steady water intake
- Avoid physically demanding activity and monitor body temperature
- Eat a light meal beforehand; avoid use on an empty or overly full stomach
Set & Setting
25E-NBOMe's narrow safety margin makes environmental control more critical than with classical psychedelics. A calm, familiar indoor environment with temperature regulation is strongly preferred — overheating is a life-threatening NBOMe complication. A sober, trusted sitter who knows the substance was taken and can recognize signs of medical emergency is essential, not optional.
Aftercare & integration. The stimulating, body-heavy nature of the experience can leave people physically drained. Rest, light nutrition, and hydration are priorities in the hours after effects subside. Sleep may be difficult for several hours — this is expected and not cause for alarm.
If the experience was psychologically difficult, allow time to process before drawing conclusions. Journaling or talking with a trusted person within the first few days can help integrate challenging material. Persistent visual disturbances, anxiety, or mood changes lasting more than a week warrant consultation with a mental health professional familiar with psychedelic experiences.
Recovery & Support
Compulsive use of NBOMe compounds is rare, but patterns of problematic use can develop. If use is escalating, interfering with daily life, or being used to avoid difficult emotions, support resources are available.
Peer support through psychedelic harm reduction organizations offers non-judgmental guidance. Professional support from therapists experienced with substance use and psychedelic integration is the most effective resource for persistent difficulties.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate help if the person experiences seizures, a body temperature hot to the touch, chest pain, loss of consciousness, uncontrollable violent agitation, or complete dissociation from reality with risk of self-harm. An uncomfortable but manageable psychedelic experience — anxiety, confusion, mild nausea — is distinct from a medical emergency.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Place the person in the recovery position if unconscious but breathing
- 3. Move to a cool environment and begin active cooling if body temperature is dangerously elevated — remove excess clothing, apply cool water to skin
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others
- 5. Do not induce vomiting (sublingual absorption means the substance is not in the stomach)
What to tell the dispatcher: Name the substance (25E-NBOMe or "an NBOMe compound"), the approximate dose and time taken, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
25E-NBOMe is not explicitly named in most controlled substance schedules but falls under structural analog provisions or structural catch-all definitions in major jurisdictions. Brazil is a notable exception, having explicitly listed it by name in 2014.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (Federal) | Not explicitly scheduled; subject to Federal Analogue Act | 25I/25C/25B-NBOMe permanently Schedule I (September 2016).[10] 25E-NBOMe prosecutable as substantially similar compound when intended for human consumption. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled since June 2014 under N-benzylphenethylamine catch-all clause.[11] |
| Canada | Schedule III (CDSA) | Controlled since October 2016 under "2C-phenethylamines and their salts, derivatives, isomers" catch-all.[11] |
| Brazil | Controlled (ANVISA) | Explicitly listed by name in February 2014.[11] |
| Russia | Controlled | NBOMe series controlled since October 2011.[11] |
| Sweden | Controlled | NBOMe series added to controlled substances list, August 2013.[11] |
| Israel | Controlled | NBOMe series controlled since May 2013.[11] |
| Australia | Likely Schedule 9 (Prohibited Substance) | Expected to fall under phenethylamine derivative analogue provisions.citation needed |
Analogue act considerations
In the United States, 25E-NBOMe is prosecutable under the Federal Analogue Act when intended for human consumption. With 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe permanently in Schedule I,[10] 25E-NBOMe differs only in its 4-position substituent — making it a straightforward analogue act target.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- LSD · Psilocin · 25I-NBOMe
Toxicity
No controlled toxicity data exist for 25E-NBOMe specifically. No lethal dose has been established in any species, and no deaths have been attributed to 25E-NBOMe alone.safety citation needed
The NBOMe class produces a consistent pattern of toxic effects: rapid heart rate, high blood pressure, dangerously elevated body temperature, sweating, dilated pupils, agitation, seizures, and excited delirium.[5][17][15] By class membership, 25E-NBOMe is presumed to carry comparable risks.
Severe complications
Severe outcomes documented for other NBOMe congeners include muscle breakdown (linked to seizures, overheating, and vasoconstriction),[9] blood clotting dysfunction, dangerously low blood sugar, metabolic acidosis, and multiple organ failure.[5] Fatal intoxications have been confirmed for 25B-NBOMe and 25I-NBOMe.[6]
Animal studies show the broader NBOMe class causes developmental harm, tissue damage, cardiovascular toxicity, and behavioral changes.[17] A subtle DNA-damaging effect was observed for 25B-NBOMe;[18] whether this generalizes to 25E-NBOMe is unknown.
Dosing unpredictability
Uneven distribution of compound on blotter paper — demonstrated through advanced imaging techniques — creates inherent overdose risk, as individual tabs may contain doses far exceeding the intended amount.[7] This variability, combined with microgram-range active doses, narrows the margin of safety substantially.
Detection
25E-NBOMe is not detectable by standard drug screens.[19] Confirmation requires specialized laboratory analysis with appropriate reference standards.[20][3]
Psychological Risks
Acute psychological adverse effects documented for the NBOMe class include severe anxiety, panic attacks, psychosis-like states (hallucinations, paranoid thinking, thought disorganization), and violent agitation.[5][17] Agitation and uncontrollable violent behavior are more prominent with NBOMe compounds than with classical psychedelics such as LSD or psilocybin, likely reflecting the broader receptor profile.[17]
Persistent effects including HPPD (HPPD) and lasting psychosis have been reported for the NBOMe class. No published case reports of persistent psychological effects specific to 25E-NBOMe were identified.safety citation needed
Tolerance & Dependence
Rapid tolerance is expected via 5-HT₂A downregulation following repeated use.[4] Cross-tolerance exists between psychedelic 5-HT₂A agonists, meaning recent use of LSD, psilocin, 25I-NBOMe, or other serotonergic psychedelics will blunt 25E-NBOMe's effects and vice versa.[4]inferred
Physical dependence is not expected based on psychedelic class pharmacology. However, rodent studies demonstrated reward-seeking behavior with 25E-NBOMe via a D1 dopamine receptor pathway,[14] providing preclinical evidence of reinforcement potential. No human dependence or withdrawal cases have been reported for 25E-NBOMe or the broader NBOMe class.
Drug Interactions
No human drug interaction studies exist for 25E-NBOMe. The following interactions are inferred from its mechanism of action.inferred
Serotonergic drugs: Combining a potent 5-HT₂A agonist with any drug that increases serotonin activity — including MAOIs, SSRIs, SNRIs, tricyclic antidepressants, lithium, tramadol, triptans, and MDMA — carries risk of serotonin syndrome.[17][5]safety citation needed
Lithium: Anecdotally linked to increased seizure risk with serotonergic psychedelics. NBOMe compounds independently lower the seizure threshold, making this combination particularly dangerous.safety citation needed
CYP2D6 and CYP3A4 inhibitors: Drugs that inhibit these liver enzymes (fluoxetine, paroxetine, bupropion, ketoconazole) could theoretically slow clearance and increase toxicity risk.inferred
Stimulants: Co-use with cocaine or amphetamines would be expected to compound cardiovascular toxicity — dangerously high blood pressure, elevated body temperature, and rapid heart rate — through additive stimulation.inferred
Cannabis: May unpredictably intensify or alter the psychedelic experience.citation needed
Contraindications
10 knownNo substance-specific contraindication data exist. The following are inferred from NBOMe class pharmacology.inferred
Heart conditions: The stimulant-like toxic effects (high blood pressure, rapid heart rate, blood vessel constriction) make 25E-NBOMe contraindicated in individuals with pre-existing cardiovascular disease.[5]
Seizure disorders: NBOMe compounds lower the seizure threshold; epilepsy or any seizure predisposition is a contraindication.[5][17]
Psychotic disorders: Personal or family history of schizophrenia or schizoaffective disorder is a contraindication given the psychosis-inducing potential of potent 5-HT₂A agonists.[17]
Concurrent serotonergic medications: MAOIs, SSRIs, SNRIs, or lithium are contraindicated due to serotonin syndrome risk.safety citation needed
Liver impairment: 25E-NBOMe undergoes extensive liver metabolism;[16] impaired liver function could reduce clearance and increase toxicity.
Pregnancy: Animal data show developmental harm from NBOMe exposure.[17]
Harm Reduction[edit]
Forms & Identification
The critical identification challenge with 25E-NBOMe is that it appears on blotter paper indistinguishable from LSD — same size, same format, same microgram-range dosing. A pronounced bitter, numbing taste on sublingual contact is the most immediate field indicator that a blotter contains an NBOMe compound rather than LSD, which is tasteless. Reagent testing can differentiate NBOMe compounds from LSD but cannot distinguish between individual NBOMe series members. Quantitative analysis of blotter content requires laboratory methods unavailable in field settings.
Guidelines
- Test every blotter with a reagent kit before use — a bitter, numbing taste on contact indicates an NBOMe compound, not LSD
- Start with the lowest available dose; do not redose during the experience
- Choose a calm, temperature-controlled indoor environment
- Ensure a sober, trusted sitter is present who knows what was taken and when
- Stay hydrated with moderate, steady water intake
- Avoid physically demanding activity and monitor body temperature
- Eat a light meal beforehand; avoid use on an empty or overly full stomach
Set & Setting
25E-NBOMe's narrow safety margin makes environmental control more critical than with classical psychedelics. A calm, familiar indoor environment with temperature regulation is strongly preferred — hyperthermia is a life-threatening NBOMe complication, and overheated or physically demanding settings increase the risk.
A sober, trusted sitter who knows the substance was taken and can recognize signs of medical emergency is essential, not optional. The sitter should know the dose taken and the time of administration.
Aftercare & integration. The stimulating, body-heavy nature of the NBOMe experience can leave users physically drained. Prioritize rest, light nutrition, and hydration in the hours following the experience. Sleep may be difficult for several hours after effects subside — this is expected and not cause for alarm.
If the experience was psychologically difficult, allow time to process before drawing conclusions. Journaling or talking with a trusted person within the first few days can help integrate challenging material. Persistent visual disturbances, anxiety, or mood changes lasting more than a week warrant consultation with a mental health professional familiar with psychedelic experiences.
Recovery & Support
Compulsive use of NBOMe compounds is rare, but psychological patterns of problematic use can develop. If use is escalating in frequency, interfering with daily functioning, or being used to avoid processing difficult emotions, support resources are available.
Peer support communities such as those at psychedelic harm reduction organizations can provide non-judgmental guidance. Professional support from therapists experienced with substance use and psychedelic integration is the most effective resource for persistent difficulties.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate help if the person experiences seizures, a body temperature hot to the touch, chest pain, loss of consciousness, uncontrollable violent agitation, or complete dissociation from reality with risk of self-harm. An uncomfortable but manageable psychedelic experience — anxiety, confusion, mild nausea — is distinct from a medical emergency.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Place the person in the recovery position if unconscious but breathing
- 3. Move to a cool environment and begin active cooling if body temperature is dangerously elevated — remove excess clothing, apply cool water to skin
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others
- 5. Do not induce vomiting (sublingual absorption means the substance is not in the stomach)
What to tell the dispatcher: Name the substance (25E-NBOMe or "an NBOMe compound"), the approximate dose and time taken, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
25E-NBOMe is not explicitly named in many controlled substance schedules but falls within structural analog provisions or catch-all structural definitions in most major jurisdictions. The more prevalent congeners — 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe — were scheduled by name, while 25E-NBOMe's legal status derives primarily from structural similarity provisions. Brazil is a notable exception, having explicitly listed 25E-NBOMe by name in 2014.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (Federal) | Not explicitly scheduled; subject to Federal Analogue Act | 25I/25C/25B-NBOMe permanently Schedule I (September 2016).[10] 25E-NBOMe prosecutable as substantially similar compound when intended for human consumption. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled since June 2014 under N-benzylphenethylamine catch-all clause.[11] |
| Canada | Schedule III (CDSA) | Controlled since October 2016 under "2C-phenethylamines and their salts, derivatives, isomers" catch-all.[11] |
| Brazil | Controlled (ANVISA) | Explicitly listed by name in February 2014.[11] |
| Russia | Controlled | NBOMe series controlled since October 2011.[11] |
| Sweden | Controlled | NBOMe series added to controlled substances list, August 2013.[11] |
| Israel | Controlled | NBOMe series controlled since May 2013.[11] |
| Australia | Likely Schedule 9 (Prohibited Substance) | Expected to fall under phenethylamine derivative analogue provisions.citation needed |
Analogue act considerations
In the United States, 25E-NBOMe's legal exposure rests on the Federal Analogue Act (21 U.S.C. § 813), which treats substances "substantially similar" to Schedule I compounds as Schedule I when intended for human consumption. With 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe permanently in Schedule I,[10] 25E-NBOMe — differing only in the 4-position substituent — is a straightforward analogue act target. Case law on NBOMe analogue prosecutions has grown since 2014, though no published appellate decision specifically addressing 25E-NBOMe was identified.
Frequently asked questions
What is 25E-NBOMe?
25E-NBOMe is a synthetic psychedelic phenethylamine of the 25x-NBOMe series, the N-(2-methoxybenzyl) derivative of 2C-E. It acts as a full agonist at 5-HT₂A and 5-HT₂C receptors with subnanomolar potency; no controlled human data exist.
How long does 25E-NBOMe last?
Total duration by route of administration — Sublingual: 4 – 10 hours; Insufflated: 3 – 7 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 25E-NBOMe?
Psychedex publishes a dosage table for 25E-NBOMe on this page covering these routes of administration: sublingual, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 25E-NBOMe?
The highest-severity documented interactions for 25E-NBOMe: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 25E-NBOMe addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 25E-NBOMe: tolerance builds rapid; full reset takes 10 days; cross-tolerance develops with LSD, Psilocin, 25I-NBOMe, 25B-NBOMe, 25C-NBOMe, DOI, Mescaline. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. — Biochemical Pharmacology doi:10.1016/j.bcp.2018.09.024
- [2]
- [3]
- [4] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [5]
- [6] ^abcShanks KG, Sozio T, Behonick GS (2015) Fatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014. — Journal of Analytical Toxicology doi:10.1093/jat/bkv058
references
- [1] ^abcEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. — Biochemical Pharmacology doi:10.1016/j.bcp.2018.09.024
- [2]
- [3]
- [4] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [5]
- [6] ^abcShanks KG, Sozio T, Behonick GS (2015) Fatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014. — Journal of Analytical Toxicology doi:10.1093/jat/bkv058